油菜叶绿体核糖体蛋白基因rps7的克隆和序列分析

从甘蓝型油菜（Ｂｒａｓｓｉｃａ ｎａｐｕｓ ｃｖ．Ｈ１６５）叶绿体基因组克隆得到了编码核糖体蛋白的基因ｒｐｓ７。经序列分析得知，该基因编码区包含个核苷酸，编码一个分子量为２０ １０９ Ｄ、由１５５个氨基酸组成的蛋质。该基因的核苷酸和编码的氨基酸序列与烟草对应基因的同源性皆高达９７％；而与水稻对应基因的同源性为９０％和８４％。该基因不含内含子，没有典型的ＳＤ序列，但在５’端－２５～－２２位发现一个与     

柽柳金属硫蛋白基因的克隆及序列分析

用木麻黄(Casuarina glauca)的金属硫蛋白基因(metallothionein 1)氨基酸序列对柽柳ESTs序列本地数据库进行tBlastn检索,获得了柽柳金属硫蛋白基因全长cDNA序列,去除polyA后该基因全长366 bp,其中5′非翻译区97 bp,3′非翻译区59 bp,开放读码框(ORF)长210 bp,编码70 个氨基酸组成的多肽,蛋白分子量为6.793 kD,理论等电点为4.99,含10个Cys,集中分布在肽链的N端和C端。BlastP同源性分析表明该基因与花生同源性最高,与小豆同源性最低。该基因的EST序列在GenBank登录(登录号：CV792539)。     

烟草渗调蛋白基因的分离克隆及序列分析

参照国外报道的渗调蛋白基因序列,自行设计并合成了一对寡核苷酸引物,通过ＰＣＲ技术从云南地方栽培的烤烟品种“红花大金元”基因组ＤＮＡ中直接扩增出了其全编码序列。ＰＣＲ产物纯化后直接克隆到ｐＧＥＭ－Ｔ载体系统中,转化大肠杆菌ＤＨ５α,在Ｘｇａｌ平板上筛选白色菌落,经ＳｐｈＩ和ＳａｃＩ双酶切,鉴定所得的重组质粒中含有７５３ｂｐ左右的ＰＣＲ扩增片段。采用双链双脱氧法定序分析表明所克隆的渗调蛋白基因编码区序列与国外迄今所报道的两个株系的序列完全一致,提示了该基因在进化上的保守性     

四个烙铁头蛇毒凝集素样蛋白基因的克隆与序列分析

从烙铁头蛇（Trimeresurus mucrosquamatus)的毒腺中提取mRNA,利用RT－PCR进行体外扩增,获得凝集素样蛋白基因,克隆至PMD18－T载体中,筛选出4种凝集素样蛋白基因（命名为TML-1、MTL－2、TML－3和TML－4）。由基因序列推导出的氨基酸序列表明：TML－1,2,3,4序列中均有CRD结构。序列同源性比较和Cys位点分析推测：TML－1和TML－2可能分别是类似于flavocetin-A的蛇毒凝集素样蛋白的α亚基和β亚基;TML－3可能类似于GPIb-bp的蛇毒凝集素样蛋白的α亚基,TML－4则可能是类似于Ⅸ/Ⅹ-bp的蛇毒凝集素样蛋白的β亚基。     

丙型肝炎病毒核心蛋白基因的克隆与表达

以含有丙型肝炎病毒核心蛋白基因的质粒pJLA502-C为模板,用PCR方法重新扩增克隆了核心蛋白基因,在扩增基因的上下端分别增加了NCOⅠ及SalⅠ酶切位点。将克隆的基因酶切后插入表达载体pBV221内,转化大肠肝菌DH_(5α),获得表达非融合核心蛋白的工程菌,42℃热诱导5hr,表达蛋白占菌体蛋白总量的15％。经包涵体纯化及分子筛纯化等,获得核心蛋白,经ELISA及Western Blotting分析表明有较好的抗原性和特异性。     

乙肝病毒表面抗原基因在胡萝卜中的克隆及表达

构建HBV表达抗原（HBsAg)植物表达载体并在胡萝卜植株中表达。采用自行构建adr亚型HBsAg基因克隆T-adr,再次酶切获得860bp含PreS2的HBsAg基因片段,将其插入到植物表达载体pBPC55,新质粒命名为pBPC91adr。将其与含除草剂抗性基因及GUS蛋白基因的筛选质粒pBPC93共同经基因枪（PDS-1000/He)转化胡萝卜悬浮细胞,经含除草剂（Biolaphos)的培养基筛选及植物激素诱导分化,获得除草剂抗性胡萝卜幼苗,结果为转化后8周,自胡萝卜细胞中分化出除草剂抗性胡萝卜幼苗,提取新分化幼苗总DNA,特异性引物PCR扩增后可见860bp扩增带;Southern-Blot证明有HBsAg基因整合,胡萝卜蛋白萃取物的Western-Blot及ELISA检测证实有HBsAg蛋白表达。利用基因枪转化使质粒pBPC91adr中HBsAg基因在胡萝卜幼苗内整合并表达,提示以植物生产疫苗具有可行性。     

棉花水孔蛋白基因的克隆及序列分析

采用RT-PCR的方法,根据GenBank上公布的棉花水孔蛋白基因序列设计引物,克隆得到4个棉花质膜水孔蛋白基因,分别为GhPIP1;1、GhPIP1;2、GhPIP2;1和GhPIP2;2,测序结果与公布序列的相似性都在98%以上,氨基酸序列在99%以上。这是首次从新陆早系列棉花(Gossypium hirsutum)的叶片中克隆得到,为以后研究棉花的质膜水孔蛋白提供参考。     

柞蚕热休克蛋白70基因的克隆和序列分析

HSP70蛋白是受热等因素刺激后而诱导产生的蛋白质,是热休克蛋白家族中最重要的一员。采用RT-PCR方法克隆了柞蚕(Antheraea pernyi)热休克蛋白70基因(HSP70)的ORF序列(GenBank登录号:GU945199),该片段的序列长度为1905bp。生物信息学分析表明,该序列共编码634个氨基酸,预测蛋白的等电点和分子量大小分别为5.62kD和69.5kD。具有HSP70的保守性结构特征,与天蚕(Antheraea yamamai)、家蚕(Bombyx mor)、甘蓝夜蛾(Mamestra brassicae)、棉铃虫(Heliothis viriplaca)、甜菜夜蛾(Spodoptera exigua)、烟草夜蛾(Manduca sexta1)、膜翅目寄生蜂(Cotesia rubecula)的同源性分别为95.7%、78.5%、76.1%、77.3%、76.6%、74.7%、65.9%。根据它们的一级结构构建了系统进化树,进一步确立了它们之间的亲缘关系。     

乙型肝炎病毒核心蛋白变构调节剂的研究进展

由于乙型肝炎病毒(hepatitis B virus,HBV)的共价闭合环状DNA的持续存在和病毒介导的宿主免疫反应钝化,导致慢性乙型肝炎病毒感染很难治愈。现有的核苷(酸)类似物或聚乙二醇干扰素疗法难以实现高比率的HBV表面抗原清除。目前正在研发的核心蛋白变构调节剂有望大幅度降低血清表面抗原。本文就HBV核心蛋白的结构、功能以及核心蛋白变构调节剂的分类、应用前景等方面进行综述。     

丙型肝炎病毒C区基因的克隆与分析

通过RT－PCR从1份来自甘肃武威地区献血员HCV阳性血清顺克隆到573bp的HCV核心基因全片段,用T－A克隆载体法将该片段接入克隆载体pUC19中并测序,结果表明武威地区分离株与Ⅰ型株HCV－Ⅰ和Ⅱ型株HCV－HeBei在该基因区段的核苷酸／氨基酸序列同源性分别为89.6%／95.4%、97.3%／97.4%,属于Ⅱ型株。     

Quantitative analysis of the interaction between the envelope protein domains and the core protein of human hepatitis B virus

Interaction between preformed nucleocapsids and viral envelope proteins is critical for the assembly of virus particles in infected cells. The pre-S1 and pre-S2 and cytosolic regions of the human hepatitis B virus envelope protein had been implicated in the interaction with the core protein of nucleocapsids. The binding affinities of specific subdomains of the envelope protein to the core protein were quantitatively measured by both ELISA and BIAcore assay. While a marginal binding was detected with the pre-S1 or pre-S2, the core protein showed high affinities to pre-S with apparent dissociation constants (K(D)(app)) of 7.3+/-0.9 and 8.2+/-0.4microM by ELISA and BIAcore assay, respectively. The circular dichroism analysis suggested that conformational change occurs in pre-S through interaction with core protein. These results substantiate the importance of specific envelope domains in virion assembly, and demonstrate that the interaction between viral proteins can be quantitatively measured in vitro.     

Dynamic changes of hepatitis B virus polymerase gene including YMDD motif in lamivudine-treated patients with chronic hepatitis B

The mutation of YMDD motif of hepatitis B virus (HBV) polymerase gene is the most frequent cause in HBV resistant to lamivudine. The aim of the study was to investigate variation features of HBV polymerase gene in chronic hepatitis B (CHB) patients before and after lamivudine treatment. From the serum samples of five CHB patients before and after 12 months of lamivudine treatment, HBV polymerase gene was amplificated and positive DNA fragments were cloned into JM105 competent cell. Twenty positive clones of every sample were checked with mismatched polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and YMDD variants were sequenced. Among five patients after 12 months of lamivudine treatment, M552I mutations in two patients with HBV DNA rebounding and D553G mutation in one non-responder were detected except two patients with negative HBV DNA consecutively. In summary, D553G mutation is probably one of the reasons that caused non-responders during lamivudine treatment. The mutations of YMDD motif occurred after lamivudine treatment are caused by the induction of lamivudine.     

乙型肝炎病毒核心抗原及Flt3配体双表达核酸疫苗的小鼠免疫应答研究

目的 构建乙型肝炎病毒核心抗原(HBcAg)和Flt3配体(FL)胞外段双表达核酸疫苗,并观察其免疫原性。方法 分别将HBcAg、FL基因克隆入pJW4303载体,获得双表达核酸疫苗,体外转染293T细胞检测目的基因的表达。分组免疫BABL／c小鼠,酶联免疫吸附试验(ELISA)检测小鼠血清抗-HBc IgG效价,酶联免疫斑点试验(ELISPOT)检测HBcAg特异性Th1／Th2型细胞因子的分泌水平。结果 所构建疫苗在体外均能表达HBcAg和FL,当基因位于内部核糖体切入位点(IRES)元件上游时表达水平明显较优。pJW4303／C／FL免疫组产生的抗-HBc IgG效价和Th1／Th2型细胞因子的分泌水平均显著优于pJW4303／C和pJW4303／FL／C组。结论 成功构建双表达核酸疫苗,基因位于上游时表达水平高于下游。FL基因的引入明显增强了HBcAg核酸疫苗的免疫原性。     

Vaccine- and hepatitis B immune globulin-induced escape mutations of hepatitis B virus surface antigen

Hepatitis B virus surface antigen (HBsAg) vaccination has been shown to be effective in preventing hepatitis B virus (HBV) infection. The protection is based on the induction of anti-HBs antibodies against a major cluster of antigenic epitopes of HBsAg, defined as the 'a' determinant region of small HBsAg. Prophylaxis of recurrent HBV infection in patients who have undergone liver transplantation for hepatitis B-related end-stage liver disease is achieved by the administration of hepatitis B immune globulins (HBIg) derived from HBsAg-vaccinated subjects. The anti-HBs-mediated immune pressure on HBV, however, seems to go along with the emergence and/or selection of immune escape HBV mutants that enable viral persistence in spite of adequate antibody titers. These HBsAg escape mutants harbor single or double point mutations that may significantly alter the immunological characteristics of HBsAg. Most escape mutations that influence HBsAg recognition by anti-HBs antibodies are located in the second 'a' determinant loop. Notably, HBsAg with an arginine replacement for glycine at amino acid 145 is considered the quintessential immune escape mutant because it has been isolated consistently in clinical samples of HBIg-treated individuals and vaccinated infants of chronically infected mothers. Direct binding studies with monoclonal antibodies demonstrated a more dramatic impact of this mutation on anti-HBs antibody recognition, compared with other point mutations in this antigenic domain. The clinical and epidemiological significance of these emerging HBsAg mutants will be a matter of research for years to come, especially as data available so far document that these mutants are viable and infectious strains. Strategies for vaccination programs and posttransplantation prophylaxis of recurrent hepatitis need to be developed that may prevent immune escape mutant HBV from spreading and to prevent these strains from becoming dominant during the next decennia.